Latest Breaking News On - Angelos stergiou - Page 12 : comparemela.com

SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue Without any Modifications

SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue Without any Modifications
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Angelos stergiouBruce mackleLifesci advisorsLife sciences group incGenfleet therapeutics shanghai incMemorial sloan kettering cancer centerData monitoring committeeAnalysis expectedSciences groupIndependent data monitoring committeeChief executive officerGenfleet therapeuticsAnnual reportSci advisors

SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2023 Financial Results

SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2023 Financial Results
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Memorial sloan kettering cancer centerNew yorkUnited statesBruce mackleJoshua zeidnerAngelos stergiouOmer jamyTapan kadiaUniversity of texas md anderson cancer centerMd oneal comprehensive cancer centerMerck sharp dohmeUniversity of alabamaLifesci advisorsLife sciences provides businessGenfleet therapeutics shanghai incLife sciences group inc

SELLAS Life Sciences Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma

SELLAS Life Sciences Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United statesBruce mackleDragan cicicAngelos stergiouNational cancer instituteLifesci advisorsLife sciences group incClinical developmentGenfleet therapeutics shanghai incBristol myers squibbMemorial sloan kettering cancer centerPrimary endpointEfficacy endpoint both metClinical activityIncreased survivalMedian overall survival

SELLAS Life Sciences (SLS) Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo

SELLAS Life Sciences (SLS) Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDragan cicicAngelos stergiouSellas life sciences group incNational cancer instituteMemorial sloan kettering cancer centerGenfleet therapeutics shanghai incLife sciences group incClinical developmentBristol myers squibbInvestor contact bruce macklemanaging directorlifesci advisorsSciences groupWilms tumorGenfleet therapeuticsLooking statementsthisAnnual report

Galinpepimut-S Plus Nivolumab Provides Survival Benefits With Acceptable Safety in Mesothelioma

The combination of galinpepimut-S and nivolumab provided positive survival outcomes with an acceptable safety profile in patients with malignant pleural mesothelioma who were refractory to or relapsed after at least 1 line of standard treatment.

Dragan cicicSloan ketteringAngelos stergiouLife sciences group incSellas life sciences group incClinical developmentLife sciencesWilms tumorMemorial sloan ketteringSciences groupAccessed juneLife sciences group